TLDR Johnson & Johnson gains momentum after FDA approves Imaavy for rare blood disorder. JNJ expands cancer care reach after Europe approves Tecvayli combination treatment. New approvals strengthen Johnson & Johnson’s growing immunology and oncology portfolio. Imaavy and Tecvayli...
Johnson & Johnson (JNJ) Stock: Surge as FDA Approval and European Cancer Treatment Expansion Drive Market Attention
其他语言标题
- 한국어존슨앤드존슨(JNJ) 주가: FDA 승인 및 유럽 암 치료 확장이 시장의 관심을 끌며 급등